Biosimilars - Market Events And Forecast - Market Event Analysis
Event Analysis
Henlius / Accord Launch the First MAb Biosimilar Developed in China into the European Market
Zydus Cadila Launches the Worldu2019s First Trastuzumab Emtansine Biosimilar in India
September 2021
Fujifilm Kyowa Kirin Biologics and Mylan EPD Launch First Adalimumab Biosimilar in Japan
April 2021
The FDA's New Guidance on Insulin Biosimilar Development
December 17, 2019
Increasing Insurer Coverage of Biosimilars in the United States
August 27, 2019
The Future Impact of Authorized Generics on the Biologics Market
June 20, 2019
The Race for Pegfilgrastim Biosimilars in the United States and Europe
September 5, 2018
The Race for Pegfilgrastim Biosimilars in the United States and Europe
Approval of the First ESA Biosimilar in the United States
June 25, 2018
Ontruzant's EC Approval
April 19, 2018
AbbVie Settles with Amgen on Humira Patents
October 6, 2017
A Step Forward for Oncology Monoclonal Antibody Biosimilars
October 2, 2017
Coherus's CHS-1701 Rejected by the FDA
June 22, 2017
The EC Approval of Celltrion's Truxima
February 27, 2017
FDA Approves the First Etanercept Biosimilar: Sandozu2019s Erelzi
September 1, 2016
Remaining U.S. Roadblocks to Inflectra Adoption Postapproval
May 23, 2016
Ten Years of Biosimilars: Insights from the 14th Annual Biosimilar Medicines Group Congress
May 19, 2016
Highlights from the 8th Biosimilars Congregation
March 24, 2016
The EMA Approval of Samsung Bioepisu2019s Benepali
January 25, 2016
Hamzah Aideed, M.Sc.
Hamzah Aideed, M.Sc., is a manager on the Biosimilars team at Clarivate. His team conducts both primary and secondary market research to provide in-depth analysis and key insights into biosimilars and the biopharmaceutical industry. Previously, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.
Yashu Malhotra
Yashu Malhotra, M.Pharm., is an analyst on the Biosimilars and Oncology teams at Clarivate. Previously, she was a senior analyst in the life sciences department at Course5 Intelligence. She also worked in competitive intelligence at WNS Global Services. Ms. Malhotra earned her master’s degree in pharmacy (quality assurance) from India’s Delhi Institute of Pharmaceutical Sciences and Research.
